This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Zhang F, Xiong Y, Wang W, Wu C, Qin F, Yuan J. The efficacy and safety of intralesional injection of collagenase Clostridium histolyticum for Peyronie’s disease: a meta-analysis of published prospective studies. Front Pharmacol. 2022;13:973394.
Li MK, Sigalos JT, Yoffe DA, Modiri N, Hu MY, Gaither TW, et al. Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis. J Sex Med. 2023;20:200–4.
Levine LA, Larsen SM. Surgical correction of persistent Peyronie’s disease following collagenase Clostridium histolyticum treatment. J Sex Med. 2015;12:259–64.
Cocci A, Ralph D, Djinovic R, Hatzichristodoulou G, Morelli G, Salonia A, et al. Surgical outcomes after collagenase Clostridium histolyticum failure in patients with Peyronie’s disease in a multicenter clinical study. Sci Rep. 2021;11:166.
Wymer K, Kohler T, Trost L. Comparative cost-effectiveness of surgery, collagenase clostridium histolyticum, and penile traction therapy in men with Peyronie’s disease in an era of effective clinical treatment. J Sex Med. 2019;16:1421–32.
Author information
Authors and Affiliations
Contributions
Conceptualization: RK, JNM, and SVE; Data curation: RK and KVR; Formal analysis: RK, JNM, and SVE; Investigation: RK, KVR, JNM, and SVE; Project administration: RK, KVR, JNM, and SVE; Supervision: JNM and SVE; Visualization: RK and SVE; Writing – original draft: RK, KVR, JNM, and SVE. Writing – review & editing: RK, KVR, JNM, and SVE.
Corresponding author
Ethics declarations
Competing interests
JNM serves as a consultant to Boston Scientific Corporation, Endo Pharmaceuticals, and Halozyme Therapeutics and receives compensation. KVR serves as a speaker for Boston Scientific Corporation and Halozyme Therapeutics and receives compensation. RK and SVE declare no potential conflicts of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kianian, R., Regets, K.V., Mills, J.N. et al. “Can we try to avoid surgery first?”—Real-world experience with surgery for Peyronie’s disease in the post-intralesional collagenase setting. Int J Impot Res (2023). https://doi.org/10.1038/s41443-023-00713-5
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41443-023-00713-5